Welcome to our dedicated page for Microbot Med SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Microbot Medical Inc. (NASDAQ: MBOT), a commercial stage medical device company focused on the LIBERTY Endovascular Robotic System. Through these filings, investors can review how the company reports material events, financing transactions, intellectual property developments and key commercialization steps for its endovascular robotics platform.
Microbot Medical uses current reports on Form 8-K to disclose significant milestones, including FDA 510(k) clearance for the LIBERTY System, the start of its limited market release in the U.S., and the first hospital adoption of LIBERTY for patient care at Emory University Hospital. Other 8-K filings describe partnerships with a U.S.-based third-party logistics provider to support commercialization, as well as the company’s exhibition of LIBERTY at major medical meetings.
Several 8-K filings also detail capital markets activity, such as the exercise of outstanding preferred investment options, issuance of new short-term preferred investment options and related gross proceeds. In these documents, Microbot Medical outlines intended uses of funds, including continued development, commercialization and regulatory activities for the LIBERTY Robotic System, potential acquisitions of complementary assets or products, expansion of applications derived from its IP portfolio, and working capital and general corporate purposes.
Additional filings address intellectual property events, such as the granting of the company’s first patent in Japan covering core LIBERTY System technology, and certain compensation decisions for executives and non-management directors. On Stock Titan, these filings are updated as they are made available through EDGAR, and AI-powered summaries can help explain the context and key points of each document, from material event disclosures to financing terms and governance changes related to MBOT.
Microbot Medical Inc. filed an 8-K noting it will showcase recent commercial achievements that led to the Full Market Release (FMR) of its LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference.
CEO Harel Gadot and senior executives will present live at 10:15 a.m. ET on April 15, 2026, discussing the company’s strategy, growth opportunities, and how LIBERTY aims to address physician radiation exposure, physical strain, and staffing issues. The presentation will be webcast via the company’s investor website, and management will also hold one-on-one meetings with healthcare-focused institutional investors.
The press release describing these plans is furnished as an exhibit and includes standard forward-looking statements language.
Microbot Medical Inc. is moving from a limited to a full U.S. market release of its LIBERTY® Endovascular Robotic System. The full launch is scheduled to coincide with the Society of Interventional Radiology Annual Scientific Meeting in Toronto, which brings together its primary U.S. target users.
LIBERTY, described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, has already been adopted by multiple healthcare systems, including hospitals such as Emory Healthcare and Tampa General Hospital. It has been used commercially in procedures like Prostate Artery Embolization, Uterine Fibroid Embolization, Genicular Artery Embolization, Y90 mapping and deliveries, and peripheral arterial interventions.
To support the full market release, the company has expanded its commercial organization, increasing its U.S. sales footprint from four to eight territories and setting a goal of 12 territories by the end of 2026. Management highlights physician feedback on LIBERTY’s precision, short learning curve, fast setup and the ability to use preferred wires and catheters, while also pointing to industry moves to strengthen protections against occupational radiation exposure as a supportive backdrop for remotely operated systems.
Microbot Medical Inc. proposes an at-the-market offering to sell up to $39,230,691 aggregate offering price of its common stock through H.C. Wainwright & Co., acting as sales agent, under an amended sales agreement.
As of December 31, 2025, Microbot reported 67,158,044 shares outstanding; the prospectus shows an as adjusted figure of 83,851,955 shares reflecting an assumed sale of 16,693,911 shares at an illustrative price of $2.35 per share (the April 8, 2026 closing price referenced). The offering permits sales on Nasdaq or by other methods permitted as an ATM; Wainwright’s commission is 3.0% of gross proceeds. The company discloses intended use of proceeds for LIBERTY® development, regulatory and commercialization activities, potential IP acquisitions, and general corporate purposes, and notes ongoing risks related to regional hostilities in Israel that could affect operations.
Microbot Medical Inc. is activating its existing at-the-market equity program with H.C. Wainwright & Co. Under this arrangement, the company may sell shares of its common stock, par value $0.01 per share, from time to time up to an aggregate offering price of $39,230,691.
Sales can occur on the Nasdaq Capital Market, through market makers, or directly to Wainwright in negotiated transactions at prevailing market prices or prices related to them. These sales will be made under a shelf registration statement on Form S-3, using a prospectus and a new prospectus supplement filed with the SEC. The company also filed a legal opinion from its counsel on the validity of the shares.
Microbot Medical Inc. director Aileen Ptucha Stockburger received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and are scheduled to expire on April 1, 2036.
Microbot Medical Inc. director Madden Martin J. received a grant of stock options representing 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and expire on April 1, 2036.
This is a compensation-related award, not an open-market purchase or sale, and leaves the director holding 10,000 options following the transaction.
Microbot Medical Inc. director Wenderow Tal Baruch received a grant of stock options, giving the right to buy 10,000 shares of common stock. The options have an exercise price of $2.37 per share and expire on April 1, 2036. Following this grant, Baruch holds stock options covering 10,000 shares directly.
Microbot Medical Inc. director David James Wilson received a grant of stock options covering 10,000 shares of common stock. The options were awarded at an exercise price of $2.37 per share, carry no upfront cost, and were granted on April 1, 2026.
These options give him the right to buy 10,000 shares of Microbot Medical common stock at $2.37 per share until their expiration on April 1, 2036. After this grant, he holds 10,000 stock options directly, with no additional derivative positions shown in this filing.
Microbot Medical Inc. director Burell Scott R reported receiving a grant of stock options. On April 1, 2026, he was awarded options to acquire 10,000 shares of common stock at an exercise price of $2.37 per share, expiring on April 1, 2036. Following this grant, he holds stock options covering 10,000 underlying shares directly.
Microbot Medical Inc. director Laxminarain Prattipati received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and expire on April 1, 2036.
Following this grant, Prattipati holds stock options for 10,000 shares directly. This is a compensation-related award, not an open‑market purchase or sale of Microbot Medical common stock.